{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:36:52Z","timestamp":1771065412837,"version":"3.50.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006149","name":"Oxford University Hospitals National Health Service Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006149","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gustav V:s Jubilee Foundation"},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Mrs. Berta Kamprad Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gene-expression profiling can be used to classify human tumors into molecular subtypes or risk groups, representing potential future clinical tools for treatment prediction and prognostication. However, it is less well-known how prognostic gene signatures derived in one malignancy perform in a pan-cancer context. In this study, a gene-rule-based single sample predictor (SSP) called classifier for lung adenocarcinoma molecular subtypes (CLAMS) associated with proliferation was tested in almost 15 000 samples from 32 cancer types to classify samples into better or worse prognosis. Of the 14 malignancies that presented both CLAMS classes in sufficient numbers, survival outcomes were significantly different for breast, brain, kidney and liver cancer. Patients with samples classified as better prognosis by CLAMS were generally of lower tumor grade and disease stage, and had improved prognosis according to other type-specific classifications (e.g. PAM50 for breast cancer). In all, 99.1% of non-lung cancer cases classified as better outcome by CLAMS were comprised within the range of proliferation scores of lung adenocarcinoma cases with a predicted better prognosis by CLAMS. This finding demonstrates the potential of tuning SSPs to identify specific levels of for instance tumor proliferation or other transcriptional programs through predictor training. Together, pan-cancer studies such as this may take us one step closer to understanding how gene-expression-based SSPs act, which gene-expression programs might be important in different malignancies, and how to derive tools useful for prognostication that are efficient across organs.<\/jats:p>","DOI":"10.1093\/bib\/bbab154","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T11:08:18Z","timestamp":1617620898000},"source":"Crossref","is-referenced-by-count":10,"title":["Pan-cancer application of a lung-adenocarcinoma-derived gene-expression-based prognostic predictor"],"prefix":"10.1093","volume":"22","author":[{"given":"Deborah F","family":"Nacer","sequence":"first","affiliation":[{"name":"Lund University, Sweden"}]},{"given":"Helena","family":"Liljedahl","sequence":"additional","affiliation":[{"name":"Lund University, Sweden"}]},{"given":"Anna","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Lund University, Sweden"}]},{"given":"David","family":"Lindgren","sequence":"additional","affiliation":[{"name":"Lund University, Sweden"}]},{"given":"Johan","family":"Staaf","sequence":"additional","affiliation":[{"name":"Lund University, Sweden"}]}],"member":"286","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"2021110814300328600_ref1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"2021110814300328600_ref2","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"2021110814300328600_ref3","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-13-1845","article-title":"The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer","volume":"20","author":"Filipits","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021110814300328600_ref4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2021110814300328600_ref5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Cancer Genome Atlas Research N","year":"2012","journal-title":"Nature"},{"key":"2021110814300328600_ref6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research N","year":"2014","journal-title":"Nature"},{"key":"2021110814300328600_ref7","doi-asserted-by":"crossref","first-page":"52957","DOI":"10.18632\/oncotarget.10641","article-title":"Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma","volume":"7","author":"Ringner","year":"2016","journal-title":"Oncotarget"},{"key":"2021110814300328600_ref8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-12-2321","article-title":"A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients","volume":"19","author":"Tang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021110814300328600_ref9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jnci\/djq025","article-title":"Gene expression-based prognostic signatures in lung cancer: ready for clinical use?","volume":"102","author":"Subramanian","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2021110814300328600_ref10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/annonc\/mdw683","article-title":"Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies","volume":"28","author":"Tang","year":"2017","journal-title":"Ann Oncol"},{"key":"2021110814300328600_ref11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1158\/1078-0432.CCR-15-0529","article-title":"Prognostic and chemotherapy predictive value of gene-expression phenotypes in primary lung adenocarcinoma","volume":"22","author":"Ringner","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021110814300328600_ref12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/bib\/bbz008","article-title":"Performance of gene expression-based single sample predictors for assessment of clinicopathological subgroups and molecular subtypes in cancers: a case comparison study in non-small cell lung cancer","volume":"21","author":"Cirenajwis","year":"2020","journal-title":"Brief Bioinform"},{"key":"2021110814300328600_ref13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ijc.33242","article-title":"A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis","volume":"148","author":"Liljedahl","year":"2021","journal-title":"Int J Cancer"},{"key":"2021110814300328600_ref14","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.4161\/cc.5.19.3254","article-title":"Proliferation: the most prominent predictor of clinical outcome in breast cancer","volume":"5","author":"Desmedt","year":"2006","journal-title":"Cell Cycle"},{"key":"2021110814300328600_ref15","doi-asserted-by":"crossref","first-page":"e17911","DOI":"10.1371\/journal.pone.0017911","article-title":"GOBO: gene expression-based outcome for breast cancer online","volume":"6","author":"Ringner","year":"2011","journal-title":"PLoS One"},{"key":"2021110814300328600_ref16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2009.22.8775","article-title":"Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome","volume":"28","author":"Staaf","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021110814300328600_ref17","doi-asserted-by":"crossref","first-page":"12184","DOI":"10.1038\/s41598-019-48570-x","article-title":"Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series","volume":"9","author":"Vallon-Christersson","year":"2019","journal-title":"Sci Rep"},{"key":"2021110814300328600_ref18","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1200\/JCO.2006.05.6861","article-title":"Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer","volume":"24","author":"Hess","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021110814300328600_ref19","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1158\/1078-0432.CCR-10-1265","article-title":"Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer","volume":"16","author":"Tabchy","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021110814300328600_ref20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/jnci\/djq524","article-title":"Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer","volume":"103","author":"Iwamoto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021110814300328600_ref21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"2021110814300328600_ref22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"2021110814300328600_ref23","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"2021110814300328600_ref24","volume-title":"R: A Language and Environment for Statistical Computing. Version 3.6.3","author":"R Core Team","year":"2020"},{"key":"2021110814300328600_ref25","volume-title":"Survminer: Drawing Survival Curves Using 'ggplot2'. R Package Version 0.4.8","author":"Kassambara","year":"2020"},{"key":"2021110814300328600_ref26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B Methodol"},{"key":"2021110814300328600_ref27","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-14-1087","article-title":"Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome","volume":"20","author":"Karlsson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021110814300328600_ref28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021110814300328600_ref29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.molonc.2015.11.004","article-title":"Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse","volume":"10","author":"Falato","year":"2016","journal-title":"Mol Oncol"},{"key":"2021110814300328600_ref30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/1055-9965.EPI-13-1017","article-title":"Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes","volume":"23","author":"Caan","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021110814300328600_ref31","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021110814300328600_ref32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(10)70008-5","article-title":"Breast cancer molecular profiling with single sample predictors: a retrospective analysis","volume":"11","author":"Weigelt","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021110814300328600_ref33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2164-7-96","article-title":"The molecular portraits of breast tumors are conserved across microarray platforms","volume":"7","author":"Hu","year":"2006","journal-title":"BMC Genomics"},{"key":"2021110814300328600_ref34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2021110814300328600_ref35","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower grade gliomas","volume":"372","author":"Cancer Genome Atlas Research N","year":"2015","journal-title":"N Engl J Med"},{"key":"2021110814300328600_ref36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/path.5468","article-title":"Molecular subtyping reveals immune alterations in IDH wild-type lower grade diffuse glioma","volume":"251","author":"Wu","year":"2020","journal-title":"J Pathol"},{"key":"2021110814300328600_ref37","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.celrep.2016.02.024","article-title":"Multilevel genomics-based taxonomy of renal cell carcinoma","volume":"14","author":"Chen","year":"2016","journal-title":"Cell Rep"},{"key":"2021110814300328600_ref38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-030-21540-8_6","volume-title":"Hepatocellular Carcinoma: Translational Precision Medicine Approaches","author":"Lee","year":"2019"},{"key":"2021110814300328600_ref39","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Cancer Genome Atlas Research N","year":"2017","journal-title":"Cell"},{"key":"2021110814300328600_ref40","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.18632\/aging.102923","article-title":"Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications","volume":"12","author":"Huang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2021110814300328600_ref41","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"2021110814300328600_ref42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hep.20375","article-title":"Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling","volume":"40","author":"Lee","year":"2004","journal-title":"Hepatology"},{"key":"2021110814300328600_ref43","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"2021110814300328600_ref44","doi-asserted-by":"crossref","first-page":"e36530","DOI":"10.1371\/journal.pone.0036530","article-title":"Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation","volume":"7","author":"Wilkerson","year":"2012","journal-title":"PLoS One"},{"key":"2021110814300328600_ref45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092476","article-title":"Cancer-specific immune prognostic signature in solid tumors and its relation to immune checkpoint therapies","volume":"12","author":"Das","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2021110814300328600_ref46","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-09-2509","article-title":"Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome","volume":"16","author":"Jonsson","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021110814300328600_ref47","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1158\/1078-0432.CCR-12-0343","article-title":"Molecular profiling reveals low- and high-grade forms of primary melanoma","volume":"18","author":"Harbst","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021110814300328600_ref48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/22\/6\/bbab154\/41087626\/bbab154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/22\/6\/bbab154\/41087626\/bbab154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:20:13Z","timestamp":1724772013000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbab154\/6272790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbab154","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,5,10]]},"article-number":"bbab154"}}